InvestorsHub Logo
Followers 224
Posts 31708
Boards Moderated 4
Alias Born 10/10/2005

Re: gfp927z post# 252

Friday, 04/23/2021 9:14:54 AM

Friday, April 23, 2021 9:14:54 AM

Post# of 649
Interesting comment on Seeking Alpha with Biotech Ideas


Biotechs are often "calculated Lotto tickets" with numerous variables that can cause capital losses, opportunity cost and delayed success. Clinical trial results are just one of the obstacles to realizing great investment returns. There is the concern of the need for dilution to raise capital in the event of a failed clinical trial or just to get to the point of designing a clinical trial and retaining a CRO. Patent protection and possible venture partners are variables. And experienced, motivated management is crucial.

An attractive part of investing in biotechs are the numerous potential catalysts for price movement--trial results, investment and biotech conference presentations and abstracts, research coverage updates, filings--IND,Phase I, II and III and so on.

Conversely, delays in trial results, FDA filings etc. can initiate sell offs that provide trading opportunities. And lucrative returns without any need to even have the pharmaceutical to actually get to market.
WVE has had a bump in the road, but there is an opportunity for traders new to the story to conduct their DD to assess whether or not a near term catalyst for capital appreciation exists.

There are other promising biotechs with compelling possibilities for the near term. In order of price (low to high), they are:

CTYX (soon to be changed by FINRA to CURB and new name of Curative Biotech)

OCGN (Ocugen)

GTBP (GT Biopharma)


CTYX has suffered a recent selloff from $0.18 to $0.08 from an over due approval by FINRA for the aforementioned name and ticker symbol change. All indications that this delay is due to FINRA and not the company's fault. Respected biotech management in place with patents and licenses --including with the National Institute of Health (NIH). Recent CEO blog at www.curativebiotech.com has generated a nice move off its recent lows.)
OCGN has had a tremendous run over the past few months and has established a base after an understandable profit taking attack by those fortunate to have bought at dramatically lower prices. Recent news involving COVID has revived trading volume and the stock price to over $7.00 (from below $0.60 and running to over $15).

GTBP has been reporting very positive single patient trial results on their immunotherapy treatments for cancer. The Company expects an ongoing number of trial results to be announced over the net few weeks and will be presenting at upcoming Biotech Investment Conferences. GTBP has a lot more to do before getting to broader clinical trials, but the potential for positive price moves exists with these pending announcements.

As with any biotech investment, taking profits when offered by the market is advisable because, as WVE's recent stumble has reminded us, there are no guarantees.

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.